Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor (Q43599025)

25 November 2017

Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor (English)

1 reference

25 November 2017

urinary tract infection

1 reference

Lindsay E Nicolle

1

1 reference

25 November 2017

George Capuano

series ordinal

2

1 reference

25 November 2017

Albert Fung

series ordinal

3

1 reference

25 November 2017

Keith Usiskin

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 January 2014

1 reference

25 November 2017

Postgraduate Medicine

1 reference

25 November 2017

126

1 reference

25 November 2017

7-17

1 reference

25 November 2017

1

1 reference

Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus

25 November 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Effect of glucose and pH on uropathogenic and non-uropathogenic Escherichia coli: studies with urine from diabetic and non-diabetic individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Incidence of urinary tract infection in patients with type 2 diabetes. Experience from adverse event reporting in clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozin-treated subjects with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Urinary tract infections in patients with diabetes treated with dapagliflozin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Renal glucose reabsorption inhibitors to treat diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2014.01.2720

21 January 2018

Identifiers

DOI

10.3810/PGM.2014.01.2720

1 reference

25 November 2017

1 reference